An inorganic phosphate (P(i))-restricted diet is important for patients with chronic kidney disease and patients on hemodialysis. Phosphate binders are essential for preventing hyperphosphatemia and ectopic calcification. The sodium-dependent P(i) (Na/P(i)) transport system is involved in intestinal P(i) absorption and is regulated by several factors. The type II sodium-dependent P(i) transporter Npt2b is expressed in the brush-border membrane in intestinal epithelial cells and transports P(i). In the present study, we analyzed the phenotype of Npt2b(-/-) and hetero(+/-) mice. Npt2b(-/-) mice died in utero soon after implantation, indicating that Npt2b is essential for early embryonic development. At 4 wk of age, Npt2b(+/-) mice showed hypophosphatemia and low urinary P(i) excretion. Plasma fibroblast growth factor 23 levels were significantly decreased and 1,25(OH)(2)D(3) levels were significantly increased in Npt2b(+/-) mice compared with Npt2b(+/+) mice. Npt2b mRNA levels were reduced to 50% that in Npt2b(+/+) mice. In contrast, renal Npt2a and Npt2c transporter protein levels were significantly increased in Npt2b(+/-) mice. At 20 wk of age, Npt2b(+/-) mice showed hypophosphaturia and reduced Na/P(i) cotransport activity in the distal intestine. Npt2b(+/+) mice with adenine-induced renal failure had hyperphosphatemia and high plasma creatinine levels. Npt2b(+/-) mice treated with adenine had significantly reduced plasma P(i) levels compared with Npt2b(+/+) mice. Intestinal Npt2b protein and Na(+)/P(i) transport activity levels were significantly lower in Npt2b(+/-) mice than in the Npt2b(+/+) mice. The findings of the present studies suggest that Npt2b is an important target for the prevention of hyperphosphatemia.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1152/ajprenal.00663.2010 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The transcription factor BBX regulates phosphate homeostasis through the modulation of FGF23.
Exp Mol Med
November 2024
Department of Oral Pathology and Regenerative Medicine, School of Dentistry, Institute for Hard Tissue and Bio‑tooth Regeneration (IHBR), Kyungpook National University, Daegu, Republic of Korea.
Fibroblast growth factor 23 (FGF23) plays an important role in phosphate homeostasis, and increased FGF23 levels result in hypophosphatemia; however, the molecular mechanism underlying increased FGF23 expression has not been fully elucidated. In this study, we found that mice lacking the bobby sox homolog (Bbx) presented increased FGF23 expression and low phosphate levels in the serum and skeletal abnormalities such as a low bone mineral density (BMD) and bone volume (BV), as well as short and weak bones associated with low bone formation. Osteocyte-specific deletion of Bbx using Dmp-1-Cre resulted in similar skeletal abnormalities, elevated serum FGF23 levels, and reduced serum phosphate levels.
View Article and Find Full Text PDFVitamin D suppresses Npt2c abundance and differentially modulates phosphate and calcium homeostasis in Npt2a knockout mice.
Sci Rep
July 2024
Department of Molecular Pharmacology and Physiology, Morsani College of Medicine, University of South Florida, Tampa, FL, USA.
Vitamin D is clinically used for the treatment of vitamin D deficiency or osteoporosis, partially because of its role in regulating phosphate (P) and calcium (Ca) homeostasis. The renal sodium-phosphate cotransporter 2a (Npt2a) plays an important role in P homeostasis; however, the role of vitamin D in hypophosphatemia has never been investigated. We administered vehicle or vitamin D to wild-type (WT) mice or hypophosphatemic Npt2a mice.
View Article and Find Full Text PDFEffect of an NHE3 inhibitor in combination with an NPT2b inhibitor on gastrointestinal phosphate absorption in Rodent models.
PLoS One
January 2024
Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana, United States of America.
Many of the pathological consequences of chronic kidney disease can be attributed to an elevation in serum phosphate levels. Current therapies focused on decreasing intestinal phosphate absorption to treat hyperphosphatemia are inadequate. The most effective therapeutic strategy may be to target multiple absorptive pathways.
View Article and Find Full Text PDFEffects of pharmacological inhibition of the sodium-dependent phosphate cotransporter 2b (NPT2b) on intestinal phosphate absorption in mouse and rat models.
Pharmacol Res Perspect
April 2022
Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana, USA.
An excess phosphate burden in renal disease has pathological consequences for bone, kidney, and heart. Therapies to decrease intestinal phosphate absorption have been used to address the problem, but with limited success. Here, we describe the in vivo effects of a novel potent inhibitor of the intestinal sodium-dependent phosphate cotransporter NPT2b, LY3358966.
View Article and Find Full Text PDFEnhanced phosphate absorption in intestinal epithelial cell-specific NHE3 knockout mice.
Acta Physiol (Oxf)
February 2022
Department of Molecular Pharmacology and Physiology, Morsani College of Medicine, University of South Florida, Tampa, Florida, USA.
Article Synopsis
- The kidneys are crucial for maintaining phosphate (P) balance, and patients with chronic kidney disease (CKD) often develop high phosphate levels (hyperphosphatemia); this study investigates the role of intestinal NHE3 in this process using specialized knockout mice.
- Tenapanor, an NHE3 inhibitor, was tested and showed initial inhibition of intestinal phosphate uptake, but later led to increased absorption, while knockout mice displayed enhanced P uptake and altered hormone levels in response to dietary changes.
- The findings suggest that intestinal NHE3 significantly affects phosphate regulation, challenging the understanding of how tenapanor influences phosphate homeostasis.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!